Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12338215 | 0.78 | NQO2 (0.72) | NQO1NQO2CYP19A1APPHSD17B1 | |
| SCHEMBL12115251 | 0.75 | NQO1 (0.58) | NQO1NQO2GPR3CYP19A1APP | |
| SCHEMBL16314329 | 0.75 | KDM4E (0.49) | KDM4EGPR3ADORA2ACDK4CCND1 | |
| SCHEMBL1103307 | 0.74 | KDM4E (0.48) | KDM4EGPR3PDPK1CDK4CCND1 | |
| SCHEMBL13978933 | 0.74 | NQO1 (0.57) | NQO1NQO2GPR3CYP19A1APP | |
| SCHEMBL1102744 | 0.74 | NQO1 (0.50) | NQO1NQO2KDM4ECYP19A1APP | |
| SCHEMBL12115256 | 0.73 | NQO1 (0.60) | NQO1NQO2CYP19A1APPKDM1A | |
| SCHEMBL1102985 | 0.72 | NQO1 (0.49) | NQO1NQO2KDM4ECYP19A1APP | |
| SCHEMBL13979021 | 0.72 | NQO1 (0.55) | NQO1NQO2GPR3CYP19A1APP | |
| SCHEMBL19678607 | 0.72 | NQO1 (0.55) | NQO1NQO2CYP19A1APPHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| EP-2147962-A1 | Azaanthracene-derivatives and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | NQO1 663/4885NQO2 1324/4885KDM4E 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.